Understand ulcerative colitis treatment options: A clinical guide to medicines, monitoring, and surgery

Understanding ulcerative colitis treatment options requires separating medicines that control an active flare from therapies used to maintain remission. Doctors consider how severe the inflammation is, how much of the large intestine is affected, prior treatment response, and whether complications are present. Most people require ongoing medical treatment unless the colon and rectum are removed surgically. 1

How treatment goals are defined

Ulcerative colitis treatment is designed to reduce inflammation, relieve symptoms, induce remission, maintain remission, and support healing of the intestinal lining. Remission means symptoms have disappeared or become minimal, but symptom improvement alone does not always establish that inflammation has resolved. Updated adult guidance identifies endoscopic improvement, commonly described as a Mayo Endoscopic Score of 0 or 1, as an important target associated with a greater likelihood of sustained, steroid-free remission. 6

Assessment generally combines symptoms with laboratory, stool, and endoscopic information. Blood tests may evaluate anemia, infection, and inflammation, while stool studies can help exclude bacterial, viral, or parasitic infection. Colonoscopy with biopsies is used to confirm the diagnosis and assess disease distribution, and flexible sigmoidoscopy may be selected when severe inflammation makes a full colonoscopy less suitable. 2

Options for mild-to-moderate disease

Aminosalicylates, also called 5-ASA medicines, are commonly used for mild-to-moderate ulcerative colitis and for maintaining remission. Mesalamine can deliver anti-inflammatory treatment to the colon through oral tablets or through rectal forms such as suppositories and enemas. Rectal treatment is particularly relevant when inflammation is concentrated in the rectum or lower colon, while oral and rectal 5-ASA can be combined when disease is more extensive. 1

Clinical guidance recommends rectal 5-ASA at 1 gram daily for remission induction in mildly to moderately active disease and oral 5-ASA at a minimum of 2 grams daily for mildly to moderately active extensive disease. Aminosalicylates are generally considered among the safer anti-inflammatory options because they do not broadly weaken the immune system, although uncommon effects can include headache, hair loss, kidney problems, or inflammation of the lungs or pancreas. 36

Short-term corticosteroid treatment

Corticosteroids can reduce inflammation relatively quickly during moderate-to-severe flares and may also be used when mild-to-moderate disease does not respond adequately to aminosalicylates. Depending on severity and location, treatment may be given orally, rectally, or intravenously. Intravenous corticosteroids are commonly part of hospital treatment for acute severe ulcerative colitis. 17

Steroids are generally not maintenance medicines because prolonged exposure can cause substantial harm. Reported effects include acne, increased appetite, weight gain, mood changes, and sleep difficulty, with longer-term risks including osteoporosis and cataracts. A central treatment objective is therefore to transition from steroids to a therapy that can maintain remission without continued corticosteroid exposure. 37

Advanced medicines for moderate-to-severe disease

Moderate-to-severe ulcerative colitis may require immunosuppressants, biologics, or targeted oral medicines. Biologic categories include tumor necrosis factor inhibitors, vedolizumab, ustekinumab, and interleukin-23 inhibitors. Oral targeted options include Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators such as ozanimod. Selection depends on disease activity, previous medicines, safety risks, administration preferences, and access to ongoing monitoring. 17

The American Gastroenterological Association lists infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab, and guselkumab among therapies recommended over no treatment in appropriate adults, while other medicines receive conditional recommendations. The guideline also distinguishes higher, intermediate, and lower efficacy groupings, with treatment positioning influenced by whether a person has previously received an advanced therapy. 7

Safety, monitoring, and long-term management

Advanced therapies and immunosuppressants require an assessment of potential infection and other medication-specific risks before and during treatment. Screening, vaccination review, laboratory monitoring, and evaluation of new symptoms may be necessary, particularly when medicines alter immune activity. The exact monitoring plan depends on the drug, medical history, other medicines, and local clinical protocols. 17

Ulcerative colitis commonly follows a pattern of flares and remission, so treatment does not end when symptoms improve. Doctors may use symptom review, blood tests, stool markers such as fecal calprotectin, and periodic endoscopic assessment to evaluate response or suspected relapse. A flare can be associated with infection, medication changes, stress, certain foods, or use of nonsteroidal anti-inflammatory drugs, although no trigger is identified in some cases. 56

Hospital care and surgical treatment

Acute severe or fulminant ulcerative colitis is often treated in a hospital because complications can develop quickly. Hospital management may include intravenous corticosteroids, infection testing, close clinical assessment, and rescue therapy when the initial response is inadequate. Surgery may need to be considered if severe disease does not respond to medical treatment or if dangerous complications occur. 17

Colectomy removes the colon and can eliminate ulcerative colitis from the colon, making it a potential treatment for medically refractory disease, serious complications, or precancerous or cancerous changes. Surgery is not a routine first step for most patients, and its suitability depends on disease course, overall health, surgical planning, and personal circumstances. Dietary changes may help symptoms and nutrition, but no single diet has been shown to cure ulcerative colitis. 14

How treatment choices are individualized

No single medication is appropriate for every person with ulcerative colitis. Clinicians weigh disease extent and severity alongside previous treatment response, extraintestinal symptoms such as joint or skin problems, infection history, cancer risk, pregnancy plans, other health conditions, and preferences about pills, injections, infusions, or rectal treatment. These factors can influence whether treatment is continued, intensified, changed, or combined. 17

People evaluating a treatment plan should distinguish between induction therapy, which aims to control active inflammation, and maintenance therapy, which aims to prevent recurrence. Questions about expected response, side effects, monitoring, steroid reduction, infection precautions, and alternatives are clinically relevant. Persistent bleeding, worsening diarrhea, severe abdominal pain, fever, dehydration, or marked weakness can indicate a flare requiring prompt medical assessment rather than self-directed medication changes. 51

Sources

1. National Institute of Diabetes and Kidney Diseases, Treatment for Ulcerative Colitis
2. Mayo Clinic, Ulcerative Colitis: Diagnosis and Treatment
3. Mayo Clinic, Medicines That Treat Ulcerative Colitis
4. Merck Manual Professional Edition, Ulcerative Colitis
5. National Health Service, Ulcerative Colitis
6. American College of Gastroenterology 2025 Guideline Summary, Ulcerative Colitis in Adults
7. American Gastroenterological Association 2024 Guideline Summary, Pharmacological Management of Moderate-to-Severe Ulcerative Colitis